Hyperkalemia News and Research

RSS

TPP may be an underrecognized cause of paralysis in young Hispanic men

Thyrotoxic periodic paralysis (TPP), a rare neurological condition causing limbs to go limp, may be an underrecognized cause of paralysis in young Hispanic men, a review of data by UT Southwestern Medical Center endocrinologists shows.

8 May 2023

Eating vegetables and fruits every day may reduce all-cause mortality in patients with CKD

A new study of Japanese patients with and without CKD found that a lower frequency of vegetable and fruit intake was associated with a higher risk of death regardless of CKD status.

27 Feb 2023

Novel mathematical model simulates how an average person's body regulates potassium

Having levels of potassium that are too high or too low can be fatal. A new mathematical model sheds light on the often mysterious ways the body regulates this important electrolyte.

30 Jan 2023

Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

In a recent study published in the BMJ, researchers conducted a phase three, multicenter, randomized controlled trial to evaluate the effect of using angiotensin receptor blockers that disrupt the renin-angiotensin system on the clinical outcomes of individuals with coronavirus disease 2019 (COVID-19).

21 Nov 2022

Salt substitutes reduce heart attack, stroke, and death risks

A new study provides a systematic review of the impact of salt substitutes on clinical outcomes and blood pressure for all available trials.

15 Aug 2022

Maintaining serum potassium level may lower hazard of peritonitis in patients receiving peritoneal dialysis

This prospective, multicenter, randomized controlled trial published in the American Journal of Kidney Diseases (AJKD) demonstrated that, compared with a reactive strategy of potassium supplementation when serum potassium fell below 3.5 mEq/L, a protocol-based potassium supplementation strategy to maintain serum potassium in the target range of 4-5 mEq/L resulted in a longer time (90 days) to the first peritonitis episode, a lower hazard ratio of peritonitis, and a lesser proportion of free-peritonitis participants.

18 May 2022

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Increasing sodium and calcium levels in the bloodstream helps prevent deadly arrhythmias

Blood may seem like a simple fluid, but its chemistry is complex. When too much potassium, for instance, accumulates in the bloodstream, patients may experience deadly irregular heart rhythms.

4 May 2021

Dandelion extract inhibits SARS-CoV-2 in vitro

An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.

23 Mar 2021

Rapid correction of hyperkalemia reduces mortality by half

In a new study published in the American Journal of Emergency Medicine, Adam Singer, MD, et al reported that quickly correcting high potassium levels, a condition known as hyperkalemia, in emergency department patients cut mortality in that population by half.

8 Jan 2020

New polypill cheaper, better at reducing cardiovascular disease

A new study from Beth Israel Deaconess Medical Center (BIDMC) has proved the cost-effectiveness and life-saving potential of the “polypill”: a single new pill which combines four commonly prescribed cardiovascular drugs into one to prevent a recurrent stroke or heart event in adult patients in low- and middle-income countries (LMIC).

5 Sep 2019

Indigestion remedy improves survival in people with late-stage CKD

Defined as serum bicarbonate less than 22 mmol/L, metabolic acidosis is common in people with CKD stages 4-5 (eGFR < 30 ml/min/1.73 m2) and is directly related to worsening kidney function.

17 Jun 2019

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Fewer women meet eligibility criteria for clinical trial of heart failure drugs, study finds

Clinical trial enrolment favors men, according to a study presented today at Heart Failure 2018 and the World Congress on Acute Heart Failure, a European Society of Cardiology congress. The study found that fewer women meet eligibility criteria for trials of heart failure medication.

28 May 2018

First short-acting ‘follow-on’ insulin receives FDA approval to treat diabetes

The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus.

12 Dec 2017

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

Multifunctional scales can monitor health and inform about life threatening conditions

Weighing oneself has become one of the most common morning rituals. However, your weight is not the only message that can be delivered by your bathroom scales: the team of researchers at Kaunas University of Technology Institute of Biomedical Engineering are developing the multifunctional scales, which can monitor your health and inform about potentially dangerous life conditions, such as arteriosclerosis or cardiac arrhythmia.

17 May 2017

Ardelyx initiates two clinical trials to evaluate new treatment for hyperkalemia

Ardelyx, Inc., a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced the initiation of a Phase 3 clinical trial and an onset-of-action clinical trial evaluating RDX7675 in patients with hyperkalemia, a potentially life-threatening condition common in patients with cardiorenal disease.

3 Jan 2017

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that VIVLODEX (meloxicam) capsules, a nonsteroidal anti-inflammatory drug (NSAID), is now available by prescription at pharmacies across the United States.

16 Feb 2016

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients.

7 Jan 2016